Results 21 to 30 of about 31,417,423 (292)
Blood biomarkers of neurological diseases are often employed to rule out or confirm the presence of significant intracranial or cerebrovascular pathology or for the differential diagnosis of conditions with similar presentations (e.g., hemorrhagic vs ...
Robert Murcko +3 more
doaj +1 more source
Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies [PDF]
Introduction: The pharmacokinetic properties of anti-infective drugs are a determinant part of treatment success. Pathogen replication is inhibited if adequate drug levels are achieved in target sites, whereas excessive drug concentrations linked to ...
Rajoli, Rajith K. R. +3 more
core +3 more sources
Pregnancy is associated with physiological changes that may affect drug pharmacokinetics (PKs). The aim of this study was to establish a maternal–fetal physiologically based pharmacokinetic (PBPK) model of oxcarbazepine (OXC) and its active metabolite ...
Lixia He +7 more
doaj +1 more source
Examination of Physiologically‐Based Pharmacokinetic Models of Rosuvastatin [PDF]
Physiologically‐based pharmacokinetic (PBPK) modeling is increasingly used to predict drug disposition and drug–drug interactions (DDIs). However, accurately predicting the pharmacokinetics of transporter substrates and transporter‐mediated DDIs (tDDIs) is still challenging. Rosuvastatin is a commonly used substrate probe in DDI risk assessment for new
Bowman, Christine M. +3 more
openaire +2 more sources
Background: Voriconazole is a potent antifungal drug with complex pharmacokinetics caused by time-dependent inhibition and polymorphisms of metabolizing enzymes. It also exhibits different pharmacokinetic characteristics between adults and children.
Yahui Zhang +7 more
doaj +1 more source
An introduction to physiologically‐based pharmacokinetic models
SummaryPhysiologically‐based pharmacokinetic (PBPK) models represent drug kinetics in one or more ‘real’ organs (and hence require submodels of organs/tissues) and they describe ‘whole‐body’ kinetics by joining together submodels with drug transport by blood flow as dictated by anatomy.
Richard N. Upton +2 more
openaire +3 more sources
A physiologically based pharmacokinetic model for V937 oncolytic virus in mice
Introduction: Oncolytic viruses (OVs) represent a novel therapeutic strategy in oncology due to their capability to selectively infect and replicate in cancer cells, triggering a direct and/or immune-induced tumor lysis. However, the mechanisms governing
Sara Peribañez-Dominguez +7 more
doaj +1 more source
Background: Propylthiouracil (PTU) treats hyperthyroidism and thyroid crisis in all age groups. A variety of serious adverse effects can occur during clinical use and require attention to its pharmacokinetic and pharmacodynamic characteristics in various
Chaozhuang Shen +7 more
doaj +1 more source
Unraveling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling [PDF]
Physiologically based pharmacokinetic (PBPK) models integrate both chemical- and system-specific information into a mathematical framework, offering a mechanistic approach to predict the internal dose metrics of a chemical and an ability to perform species and dose extrapolations.
Yang, Xiaoxia, Fisher, Jeffrey W.
openaire +3 more sources
Physiologically Based Pharmacokinetic Modeling of Extracellular Vesicles
Extracellular vesicles (EVs) are lipid membrane bound-cell-derived structures that are a key player in intercellular communication and facilitate numerous cellular functions such as tumor growth, metastasis, immunosuppression, and angiogenesis. They can be used as a drug delivery platform because they can protect drugs from degradation and target ...
Prashant Kumar +2 more
openaire +3 more sources

